Drug intelligence / Profile preview

PAK-20

Development stage: Unknown
Lead developer: Knowledge Research and Innovation Center
Administration: Oral

Overview

PAK-20 is an investigational herbal compound preparation developed by Knowledge Research and Innovation Center for use in an integrative treatment protocol for COVID-19. In a registered Phase 1 single-group study, it was administered orally as 1 g mixed in 250 mL of soup or meat stock twice daily for up to 12 days, alongside separate interventions including Oniater, asafoetida, herbal tea, and dietary measures. Its chemical composition, individual active constituents, pharmacologic targets, and molecular mechanism of action were not publicly specified in the identified trial registry and publication. ([irct.ir](https://www.irct.ir/trial/52742/pdf))

Beyond the preview

Go deeper on PAK-20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PAK-20.

Explore the full profile